Clinical course of ovarian cancer patients under repeated stimulation of HAMA using MAb OC125 and B43.13.
Baum
R P
RP
Department of Nuclear Medicine, University of Frankfurt, Germany.
Noujaim
A A
AA
Nanci
A
A
Moebus
V
V
Hertel
A
A
Niesen
A
A
Donnerstag
B
B
Sykes
T
T
Boniface
G
G
Hör
G
G
D000328:Adult; D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis*; D000910:Antibodies, Heterophile / Q000096:biosynthesis*; D000911:Antibodies, Monoclonal / Q000276:immunology*; D015295:Antigens, Tumor-Associated, Carbohydrate; D018283:Cystadenocarcinoma, Papillary / Q000000981:diagnostic imaging / Q000276:immunology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000000981:diagnostic imaging / Q000276:immunology*; D016719:Radioimmunodetection; D015996:Survival Rate; D014057:Tomography, X-Ray Computed
D000888:Antibodies, Anti-Idiotypic; D000910:Antibodies, Heterophile; D000911:Antibodies, Monoclonal; D015295:Antigens, Tumor-Associated, Carbohydrate